Idogen’s cell therapy for hemophilia is presented in the prominent scientific journal Haemophilia
Idogen AB (publ) announced today that the highly-ranked scientific journal Haemophilia has published the company’s “Letter to the Editor” describing ItolDC-028, the IDO 8 program’s autologous cell therapy, and its potential to revolutionize the treatment of hemophiliac patients.
Haemophilia is one of the highest-ranking global scientific journals in the field of hemophilia that has accepted the documentation submitted by Idogen’s Chief Medical Officer and the company’s medical and scientific advisers for publication. This important milestone is one that the company has spent a long time working for.
“We are extremely proud of this recognition of our unique cell therapy platform. The publication of our Letter to the Editor is key to drawing the attention of researchers and clinics globally to the advances in our IDO 8 development program. We see great potential in being able to help patients with severe hemophilia who have developed antibodies to their therapy back to a vital treatment with factor VIII without requiring the arduous and costly preliminary treatment known as ITI. Over the long term, the company also hopes to develop a therapy that can prevent the development of neutralized antibodies prior to initial treatment with factor VIII,” says Hanjing Xie, Chief Medical Officer at Idogen.
The article provides a cursory description of the current challenges in treating patients who are suffering from hemophilia and have developed antibodies to the vital factor VIII (FVIII) treatment. Furthermore, the authors explain how Idogen’s ItolDC-028 cell therapy acts at the cellular level in order to restore the body’s tolerance to FVIII. Publication of the article also demonstrates the long-term potential in autologous therapies, meaning medical treatments where the patient’s own cells are used for the purpose of treating unwanted immune responses. By way of conclusion, the company presents the design for the Phase I/IIa clinical trial as part of the IDO 8 program.
Idogen’s new acting CEO, Christina Herder, comments:
“I am extremely proud of the splendid recognition of our team’s hard work through publication in Haemophilia, the highly-regarded scientific journal. “Publication demonstrates the scientific and medical heights this program has reached, and will promote further interest in Idogen and our technological platform. It is something that will become more significant now that we are intensifying our business development efforts.”
The “Letter to the Editor” was authored by Hanjing Xie, Chief Medical Officer at Idogen; Rolf Ljung, senior professor of pediatrics and a leading expert globally in hemophilia at Lund University and member of Idogen’s Scientific Council; Jan Astermark, professor and chief physician of clinical coagulation medicine at Lund University and chief investigator in Idogen’s European Phase I/IIa clinical trial; and Therese Hylander, PhD and former researcher in the IDO 8 program at Idogen.
Read the text in its entirety at Haemophilia
http://doi.org/10.1111/hae.14663
https://onlinelibrary.wiley.com/doi/epdf/10.1111/hae.14663
For further information, please contact:
Christina Herder, Acting CEO, Idogen AB
Tel: +46 70 374 71 56
E-mail: christina.herder@idogen.com
The information was submitted for publication, through the agency of the contact person set out above, on September 20, 2022 at 08:49 a.m. CEST.
Certified Advisor:
Vator Securities AB
Idogen (Nasdaq First North Growth Market: IDOGEN) develops tolerogenic cell therapies to prevent the patient’s immune system from attacking biological agents, transplanted organs or the body's own cells or tissue. The company’s most advanced project, IDO 8, is designed to restore the efficacy of hemophilia drugs in patients who have developed neutralizing antibodies. The company’s second project, IDO T, is being developed to prevent kidney transplant rejection. In a third program, IDO AID, Idogen is focused on the treatment of autoimmune diseases. The treatment for all indications is based on the patient's own cells and is expected to have a favorable safety profile and long-lasting effect. The potential for a short-term treatment intervention to yield a long-term effect is a major advantage in health economics for both patients and divisions providing care. More information about Idogen is available via https://www.idogen.com